Penicillamine

Antirheumatic Agent — MUSCULO-SKELETAL SYSTEM

Key facts

Penicillamine is an ofp drug in the Antirheumatic Agent class catalogued in DrugCentral. It was first approved by the FDA in 1970. DrugCentral lists 1 molecular target, including dapE. Recorded indications include Cystine Renal Calculi, Cystinuria, Rheumatoid arthritis and Wilson's disease.

• Approval status: ofp (first approved 1970 by the FDA).
• Drug class: Antirheumatic Agent.
• Molecular targets: dapE (1 listed in DrugCentral).
• Indications: Cystine Renal Calculi, Cystinuria, Rheumatoid arthritis and Wilson's disease.
• ATC code: M01CC01 (Penicillamine and similar agents).
• Molecular formula: C5H11NO2S; molecular weight 149.21 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Cystine Renal Calculi
• Cystinuria
• Rheumatoid arthritis
• Wilson's disease

Off-label uses (2)

• Felty's syndrome
• Rheumatoid vasculitis

Contraindications (19)

• Agranulocytosis
• Aphthous ulcer of mouth
• Aplastic anemia
• Aplastic anemia due to drugs
• Blood in urine
• Breastfeeding (mother)
• Bronchiolitis
• Glomerulonephritis
• Goodpasture's syndrome
• Iron deficiency anemia
• Kidney disease
• Leukopenia
• Liver function tests abnormal
• Lupus erythematosus and erythema multiforme-like syndrome
• Myasthenia gravis
• Pemphigus
• Pregnancy, function
• Proteinuria
• Thrombocytopenic disorder

Mechanism & targets

• Established pharmacologic class: Antirheumatic Agent

Molecular targets (1)

Target	Gene	Action	Activity
Succinyl-diaminopimelate desuccinylase	dapE	unknown	IC50 4.30

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1970-12-04	FDA	—	ATON

ATC classification

ATC code	Therapeutic hierarchy
M01CC01	MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › SPECIFIC ANTIRHEUMATIC AGENTS › Penicillamine and similar agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Anti-neutrophil cytoplasmic antibody positive vasculitis	291.6
Proteinuria	220.7
Drug hypersensitivity	186.5
Vasculitis	154.7
Inflammation	124.7
Joint swelling	122.3
Elastosis perforans	93.2
SLE arthritis	86.6
Cardiovascular disorder	84.9
Treatment failure	79.1
Arthralgia	78.2
Elbow deformity	73.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Penicillamine is on its molecule page.

• Molecular formula: C₅H₁₁NO₂S
• Molecular weight: 149.21 g/mol
• CAS number: 52-67-5
• InChIKey: VVNCNSJFMMFHPL-VKHMYHEASA-N
• PubChem CID: 5852

CC(C)(S)[C@@H](N)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Penicillamine used for?

DrugCentral lists the following indications for Penicillamine: Cystine Renal Calculi, Cystinuria, Rheumatoid arthritis and Wilson's disease.

How does Penicillamine work?

Its molecular targets in DrugCentral include dapE.

When was Penicillamine first approved?

Penicillamine was first approved by the FDA in 1970.

What drug class does Penicillamine belong to?

Penicillamine is in the Antirheumatic Agent class.

What is the chemical formula of Penicillamine?

Penicillamine has the molecular formula C5H11NO2S and a molecular weight of 149.21 g/mol.

Sources

• DrugCentral drug card 2081 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1430 — compound record and bioactivity
• PubChem CID 5852 — chemical identifiers
• DrugBank DB00859 — drug record
• FDA UNII GNN1DV99GX — substance identity
• DailyMed: FDA labels for Penicillamine — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.